Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives
Iman Abou Dalle, Rémy Duléry, Nour Moukalled, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 19

Showing 19 citing articles:

Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma
Adam Braun, Sushanth Gouni, Astrid E. Pulles, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
Bioengineering chitosan–antibody/fluorescent quantum dot nanoconjugates for targeted immunotheranostics of non-hodgkin B-cell lymphomas
Sandhra M. Carvalho, Alexandra A.P. Mansur, Zélia Inês Portela Lobato, et al.
International Journal of Biological Macromolecules (2025) Vol. 294, pp. 139515-139515
Closed Access
Determination of the appropriate chemotherapy for patients aged 80 years or older with diffuse large B cell lymphoma
Min Jung Kim, Junhun Cho, Won Seog Kim, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-12
Open Access
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-hodgkin lymphoma
Elena Bayly-McCredie, H. Miles Prince, Costas K. Yannakou, et al.
Expert Opinion on Biological Therapy (2025)
Closed Access
Entwicklungen bei CAR-T-Zell-Therapien und bispezifischen Antikörpern
Jessica Propp, Hyatt Balke‐Want
Deleted Journal (2025)
Closed Access
Prognostic relevance of bone marrow immune cell fractions in newly diagnosed B-cell non-Hodgkin lymphoma patients
Luciana Valvano, Rocchina Vilella, Fiorella D’Auria, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access
DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma
Simar Pal Singh, Michelle D van den Beukel, Sjoerd van Deventer, et al.
(2025)
Open Access
DuoHexaBody-CD37 induces direct cytotoxic signaling in diffuse large B-cell lymphoma
Simar Pal Singh, Michelle D van den Beukel, Sjoerd van Deventer, et al.
(2025)
Open Access
Antigen Specificity: A Fluctuating Aspect in the Development of Clinical Antibodies?
Sandeep Sherawat, Suraj H. Shinde, Abhay H. Pande
Apmis (2025) Vol. 133, Iss. 1
Closed Access
Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data
Elena Bayly-McCredie, Maxine Treisman, Salvatore Fiorenza
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9736-9736
Open Access | Times Cited: 3
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review
Romana Masnikosa, Zorica Cvetković, David Pirić
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 21, pp. 11384-11384
Open Access | Times Cited: 1
The causality between gut microbiota and non-Hodgkin lymphoma: a two-sample bidirectional Mendelian randomization study
Jinjie Fu, Hao Zheng
Frontiers in Microbiology (2024) Vol. 15
Open Access
Determination of the appropriate chemotherapy for patients aged 80 years or older with diffuse large B cell lymphoma
Min Jung Kim, Junhun Cho, Won Seog Kim, et al.
Research Square (Research Square) (2024)
Open Access
Desensitization Strategies for Donor-Specific Antibodies in HLA-Mismatched Stem Cell Transplantation Recipients: What We Know and What We Do Not Know
Yang Zhou, Yu‐Lun Chen, Xi-Yi Huang, et al.
Oncology and Therapy (2024) Vol. 12, Iss. 3, pp. 375-394
Open Access
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
Daniel R. Reed, Lawrence G. Lum
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 8, pp. 761-772
Closed Access
Post-Marketing Hepatobiliary Toxicity is Associated with Worse Patients’ Survival after BiTEs Therapy: A Decade-Long Pharmacovigilance Observations from FAERS and VigiBase
Rong Hu, Junyi Shen, Aimin Jiang, et al.
(2024)
Closed Access
Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma
Dan Zou, Sitong Feng, Bowen Hu, et al.
Cell & Bioscience (2024) Vol. 14, Iss. 1
Open Access
Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies
Justyna Jureczek, Krzysztof Kałwak, Piotr Dzięgiel
Cancers (2024) Vol. 16, Iss. 24, pp. 4181-4181
Open Access
Bispecific Antibodies for Lymphoid Malignancy Treatment
Matteo Bisio, Luca Legato, Filippo Fasano, et al.
Cancers (2024) Vol. 17, Iss. 1, pp. 94-94
Open Access
Page 1

Scroll to top